Introduction
Lung cancer is the leading cause of death from cancer worldwide and is responsible for nearly one in five cancer deaths. 1 Only 17.7% of all patients with lung cancer can live ≥5 years after diagnosis. 2 Non-small-cell lung cancer (NSCLC) represents about 85% of all lung cancers. 3 Up to 69% of the advanced NSCLC patients could have a potentially actionable molecular target. 4 However, for patients with advanced NSCLC who do not fit an approved molecular targeted therapy, the standard first-line treatment remains platinum-based doublet therapy. Although targeted drugs against epidermal growth factor receptor (EGFR) have been increasingly developed for the treatment of NSCLC, unfortunately, nearly all patients eventually have disease progression due to acquired resistance.
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As an important member of the signal transducer and activator of transcription family (STAT), STAT3 is associated with malignant transformation and tumor progression. 5, 6 Constitutive activation of STAT3-meditated signal pathway plays pivotal roles in tumor cell growth, survival, apoptosis, angiogenesis and metastasis. 7, 8 Growing evidence demonstrates that constitutively activated STAT3 contributes to tumor development and progression in the majority of cancers, including breast, prostate, ovary, lung, gastric, pancreatic, melanoma and blood cancers. [9] [10] [11] [12] STAT3 is persistently activated in 22%-65% of NSCLC. [13] [14] [15] Several studies suggest that the high expression of P-STAT3 is a strong predictor of poor prognosis in patients with NSCLC. Previous findings reported that the STAT3 pathway was associated with intrinsic resistance to chemotherapeutic agents in several malignancies. 16 , 17 You et al showed that ionizing radiation induces phosphorylation of JAK2 and STAT3, and higher expression of STAT3 was found in the nucleus of radioresistant NSCLC cells.
18
STAT3 is also involved in one of the EGFR downstream pathways. 19 EGFR can directly phosphorylate STAT3, and activation of STAT3 has also been reported in NSCLC cell lines harboring activated EGFR mutations. 14, 20, 21 Studies also showed that EGFR inhibitors acting on cancer cells can activate the IL-6/JAK/STAT3 signaling pathway, thereby leading to drug resistance. 22, 23, 24 Although the response rate to EGFR tyrosine kinase inhibitor (TKI) is ~80% in EGFRmutant patients, progression-free survival is only about 1 year, as most patients eventually develop acquired resistance to the TKIs. 24 Several reports found that inhibition of STAT3 suppressed the growth of cancer cells and enhanced the sensitivity to antitumor agents in multiple types of cancer. 26, 27 Therefore, STAT3 has been considered a potential target for NSCLC therapy.
Currently, studies have focused on the antitumor properties of natural products because of their confirmed pharmacological properties and few side effects. Rhein is a lipophilic anthraquinone extensively found in medicinal herbs Rheum palmatum L., Cassia tora L. and so on, which have been used medicinally for >1,000 years. 25 Rhein has many pharmacological effects, including hepatoprotective, nephroprotective, anti-inflammatory, anticancer, antioxidant and antimicrobial activities. Although several studies have reported the mechanisms and pathways of the antitumor effect of Rhein, the direct molecular targets and specific mechanism remain unclear. 25 Diacerein, which is known to be completely metabolized into Rhein by humans and animals, is clinically prescribed for the treatment of osteoarthritis. 26 In this study, we focus on the specific molecular mechanism of action of Rhein and Diacerein that exert their antitumor effects by inhibiting STAT3.
Materials and methods
Cell culture
Human NSCLC cell lines PC-9, H460 and A549 were obtained from Shanghai Institute of Biosciences and Cell Resources Center (Chinese Academy of Sciences, Shanghai, People's Republic of China). All the cells were cultured in Roswell Park Memorial Institute-1640 media (Thermo Fisher Scientific, Waltham, MA, USA) with 10% FBS (Thermo Fisher Scientific). Cells were cultured in a humidified cell incubator with an atmosphere of 5% CO 2 at 37°C.
Antibodies and reagents
The antibodies against P-STAT3, STAT3, Bax, GAPDH, P53 and Cyclin B1 were purchased from Cell Signal Technology (Danvers, MA, USA 
Colony formation assay
Human NSCLC cells (1,000 cells/well) were seeded in sixwell plates at 37°C in 5% CO 2 atmosphere overnight. DMSO (control), Rhein (30, 60, 100 µM) or Diacerein (30, 60, 100 µM) was added to the cells for 7 days. The culture medium was replaced with fresh medium every 2 days to keep the cells growing for 7 days. Colonies were washed with PBS, fixed with 4% paraformaldehyde at room temperature for 15 minutes, washed with purified water for 3 times and stained with crystal violet for 10 minutes. Each experiment was done in triplicate for three independent experiments.
Western blot analysis
Cancer cells were seeded in six-well plates at a density of 500,000 cells/well and then incubated overnight. DMSO (control), Rhein (30, 60, 100 µM) or Diacerein (30, 60, 100 µM) was added into the six-well plates. Treated cells were washed with PBS and harvested using ice-cold RIPA lysis buffer with 1% phenylmethanesulfonyl fluoride. Proteins were separated by 10% SDS-PAGE and transferred onto a PVDF membrane, and then the blots were blocked for 2 h at room temperature with fresh 5% nonfat milk. The blots were incubated with specific primary antibodies. After washing, the membranes were incubated with the relevant secondary antibodies; visualization of bands was by enhanced chemiluminescence.
Cell apoptosis assay
PC-9 and H460 cells were seeded into six-well plates and allowed to grow to 80% confluency in complete medium. Then the cells were treated with DMSO (control), Rhein (30, 60, 100 µM) or Diacerein (30, 60, 100 µM) for 48 hours to evaluate the effects of these compounds on apoptosis. Cells were collected, washed twice in ice-cold PBS and then resuspended in binding buffer according to the instructions of the apoptosis kit. The treated cells (as described above) were simultaneously incubated with fluorescein-labeled Annexin V and PI. Annexin V-binding buffer was then added to the mixture before fluorescence was measured on a FACSCalibur (BD Biosciences, Baltimore, MD, USA). Data were analyzed using Flowjo software.
Cell cycle assay
Cells were seeded into six-well plates for 24 hours and then treated with DMSO or Rhein (30, 60, 100 µM) for 24 hours. Cells were then labeled with PI, and the cell cycle was analyzed on a FACSCalibur.
STAT3 luciferase report assay
The STAT3 luciferase reporter plasmid (pGLSTAT3-Luc) was used to detect STAT3 activation. The H460 cells were seeded in 24-well plates 24 hours before transfection. Then, the cells were co-transfected with pGLSTAT3-Luc and pRL-TK, a plasmid encoding Renilla luciferase, using Lipofectamine 3000 (Thermo Fisher Scientific) for 6 hours. Finally, the cells were treated with the indicated concentrations of Rhein for 24 hours. Luciferase activity was assessed by SpectraMax ID3 (Molecular Devices, San Jose, CA, USA). The inhibition of STAT3 activation by Rhein was calculated as the ratio between the value of firefly and Renilla luciferase activity. Experiments were performed in triplicate.
In vivo antitumor study
The Wenzhou Medical University Animal Policy and Welfare Committee approved all mouse experiments. The H460 cells (5×10 6 cells were mixed with an equal volume of PBS and Matrigel in 100 µL) were implanted on the hind flank of mice (athymic nude female mice, 5-6 weeks old). Once the tumor volumes reached ~50 mm 3 , mice were divided into three experimental groups (six mice per group, no differences in mean body weights or tumor volumes between the groups). Tumor volume was measured as V=(L×W×W)/2, in which L and W represent length and width of tumor, respectively. Animals were sacrificed on day 10, 4 hours after the last Rhein treatment. The tumors, heart, liver, kidney and lung were removed for use in the histology and Western blot analysis.
Statistical analysis
Data were expressed as mean ± SD of three independent experiments. The statistical differences between different groups were analyzed by the Student's t-test or one-way ANOVA in GraphPad Pro7.0 (GraphPad Software, Inc., La Jolla, CA, USA). P-values <0.05 were considered indicative of significance.
Results
The effect of Rhein on NSCLC cell proliferation by the MTT and colony formation assays 
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Rhein inhibits the STAT3 signaling pathway
Based on the important role of STAT3 in the process of NSCLC and the structural similarity of Rhein with the four known inhibitors of STAT3 (Napabucasin, STA-21, LLL12 and LY5), we thought that Rhein may affect the phosphorylation of STAT3. 11, 21 We tested the inhibiting ability of Rhein on STAT3 phosphorylation (P-STAT3) in NSCLC cells. Not unexpectedly, Rhein and Diacerein markedly reduced the P-STAT3 protein level in H460, A549 and PC-9 cell lines.
Rhein and Diacerein decreased P-STAT3 protein expression in NSCLC cells in a concentration-dependent manner after 24 hours of treatment; under the same condition, STAT3 protein expression remained unchanged (Figure 2A-C) . To further confirm the STAT3 inhibitory effect, we also detected the constitutive activation of STAT3 in H460 cells using STAT3 luciferase reporter assay. In agreement with the data obtained using Western blot analysis, we found Rhein significantly blocked P-STAT3 activation in a dose-dependent manner ( Figure 2D-E) . 
Rhein induces apoptosis in human NSCLC cells
To evaluate the apoptosis-inducing effects of Rhein and Diacerein in H460 and PC-9 cell lines, the cancer cells were treated with Rhein and Diacerein for 48 hours, stained with Annexin V-FITC and PI and the apoptotic cells were evaluated by flow cytometry analysis. The data showed that Rhein and Diacerein dose dependently induced cell apoptosis in PC-9 and H460 cell lines, respectively ( Figure  3A-D) . In addition, Western blot analysis data further revealed that Rhein and Diacerein increased the expression of the proapoptotic protein Bax and decreased the level of the antiapoptotic protein Bcl-2 in human NSCLC cells in a dose-dependent manner ( Figure 3E, F) . Our results also revealed that Rhein could regulate the expression of cell death-related proteins, which blocked the process of human NSCLC cell proliferation.
Rhein induces G2/M cell cycle arrest in human NSCLC cells
The cell cycle is a process involving a series of cellular events that lead to cell division and ultimately to proliferation. The entire cell cycle can be divided into four stages including the G1 phase, S phase, G2 phase and M phase (the division stage). 27 To evaluate the cell cycle arrest associated with Rhein, PC-9 and H460 cell lines were treated with Rhein for 24 hours. The percentage of Rheintreated and untreated NSCLC cells in the G2/M phase was measured by flow cytometry analysis. Rhein significantly induced the arrest of NSCLC cells in the G2/M phase of the cell cycle compared with the untreated control group (Figure 4A ), following reduced cell growth and increased apoptosis. The Western blot analysis indicated that treatment with Rhein and Diacerein dose dependently inhibited the expression of MDM2, Cyclin B1, CDC2 and P53 in H460 and PC-9 cells (Figure 4B, C) . These results indicate that the inhibition of cell proliferation by Rhein is partly associated with the induction of G2/M phase arrest in H460 and PC-9 cells.
Rhein inhibits the growth of NSCLC xenograft models
Given the potent cytotoxic activity of Rhein against human NSCLC cells, we next assessed the therapeutic efficacy of Rhein in H460 xenograft models. Mice were treated with two different doses of Rhein (60 and 100 mg/kg; intraperitoneally) every other day. Rhein led to a supra-additive reduction in growth in xenograft models ( Figure 5A-C) . Mechanistically, we found that STAT3 phosphorylation was inhibited in Rhein treatment groups ( Figure 5D ). In addition, Rhein treatment markedly increased apoptosis as indicated by the expressions of Bax and the Bcl-2 ( Figure  5D ). Importantly, the body weight of the mice was stable ( Figure 5E ). Moreover, Rhein treatment caused no gross toxicities on the heart, liver, kidney and lung compared with the control group (Figure 5F ), demonstrating excellent safety profiles.
Discussion
Recent studies highlight the importance of STAT3 in NSCLC through regulating tumor cell proliferation, survival, tumor invasion and angiogenesis. 28, 29 Several studies have implicated STAT3 activation in EGFR resistance. 22, 23 These suggest that persistent STAT3 may lead to primary resistance to targeted therapies. Thus, the IL-6/JAK/STAT3 signaling pathway seemed to be linked to primary resistance to treatments, including cytotoxic chemotherapy, radiotherapy and targeted therapy. However, up to now, no direct STAT3 inhibitor has been approved for clinical use.
The discovery of small molecular compounds for treating NSCLC is important to improve patient outcome. In this study, we have demonstrated that Rhein inhibited the STAT3 signaling pathway (Figure 2 ) and thereby induced apoptosis ( Figure 3 ) and reduced the growth of human NSCLC cells in vitro (Figures 1 and 4) . More importantly, mice treated with Rhein showed robust inhibition of tumor growth in vivo ( Figure 5 ). Diacerein as a prodrug of Rhein, a known drug for osteoarthritis, also showed the potential for inhibiting IL-6/STAT3 cancer signaling pathway. Consistent with our results, molecular investigations indicated that Diacerein-instigated apoptosis was associated with inhibition of IL-6/STAT3. 30, 31 Natural products with satisfactory clinical efficacy and low toxicity can be used as replacement therapies for many clinical diseases, and such correlative research is one of the hot topics in modern medicine. Notably, we found Rhein had few side effects on the mouse body at our therapeutic concentration ( Figure 5E, F) . Thus, the discovery of Rhein and Diacerein could speed up the development of clinical therapies for the IL-6/STAT3-dependent cancers.
Collectively, our studies demonstrate that Rhein exhibits the inhibitory potential for NSCLC growth by inhibiting 
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